Pfizer and BioNTec have said they expect to supply up to 50 million vaccine doses globally this year and up to 1.3 billion doses next year. PHOTO | FILE
A vaccine jointly developed by US pharmaceutical giant Pfizer and German biotech firm BioNTech was 90 per cent effective in preventing Covid-19 infections in ongoing Phase 3 trials, the companies announced yesterday.
The news came as soaring coronavirus cases across the world have forced millions of people back into lockdown, causing further damage to ravaged economies.
